Efinopegdutide vs Survodutide
Written by Aaron CuhaReviewed Sep 2026
The short answer
Two GLP-1 and glucagon drugs developed with the liver in mind. Efinopegdutide has been tested against semaglutide on liver fat. Survodutide has not. So their evidence is not the same shape, even though they work the same way.
- Efinopegdutide people
- 145
- Efinopegdutide nulls
- 1
- Survodutide people
- 2,034
- Survodutide nulls
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 145 people given it
Dose
Doses used in trials
0.6, 2.4, 3.6, 4.8 and 6 mg
Doses used in the survodutide trials, in mg. Not an approved ladder.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
EfinopegdutideEfinopegdutide (MK-6024), GLP-1 and glucagon receptor dual agonist
In a head-to-head test against semaglutide, it cut liver fat by 72.7 percent against 42.3 percent. Weight loss was about the same. Adding glucagon seems to do something to the liver that GLP-1 alone does not.
Column B
SurvodutideSurvodutide (GLP-1 / glucagon dual agonist)
A weekly shot still being tested. It works on two signals, GLP-1 and glucagon, and is studied for obesity and fatty liver disease.
Side by side, on the facts we can check
| What we compare | Efinopegdutide | Survodutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational. Not approved. Merck holds the rights. It came from Hanmi, and earlier went by Johnson and Johnson and Hanmi code names. | Investigational, not FDA-approved |
| Half-life | Long-acting, dosed once weekly by subcutaneous injection. No specific half-life figure was resolved in the sources loaded. | ~6 days |
| Molecular weight | Peptide conjugated to a long-acting carrier. No mass asserted; no source loaded states one. | ~4,900 Da |
| How it works | It acts on two hormone receptors at once: GLP-1 and glucagon. It is built on a long-lasting carrier, so one shot lasts a week. The GLP-1 part cuts appetite and helps blood sugar, the usual way. The glucagon part makes the liver burn more fat and make less new fat. It also raises how much energy the body burns. That is how it is meant to clear liver fat. Glucagon can push blood sugar up, which is why these drugs are balanced so the glucagon part does not dominate. | It switches on both the GLP-1 and glucagon receptors. That turns down appetite, helps the body handle sugar, burns more energy and cuts fat in the liver. |
| Studies in people | 3 | 7 |
| Evidence | Moderate: 1 completed trial, 145 people given it | Strong: 5 completed trials, 2,034 people given it |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Efinopegdutide and Survodutide?
Efinopegdutide: In a head-to-head test against semaglutide, it cut liver fat by 72.7 percent against 42.3 percent. Weight loss was about the same. Adding glucagon seems to do something to the liver that GLP-1 alone does not. Survodutide: A weekly shot still being tested. It works on two signals, GLP-1 and glucagon, and is studied for obesity and fatty liver disease.
Which has stronger research evidence, Efinopegdutide or Survodutide?
Each compound gets a band worked out from facts we counted, with the math shown. Efinopegdutide is Moderate (1 completed trial, 145 people given it). Survodutide is Strong (5 completed trials, 2,034 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Efinopegdutide and Survodutide FDA-approved?
Efinopegdutide: Investigational. Not approved. Merck holds the rights. It came from Hanmi, and earlier went by Johnson and Johnson and Hanmi code names.. Survodutide: Investigational, not FDA-approved.
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.